Amgen Inc.

Amgen Research (munich) Gmbh

Sandra Ross

Tobias Raum

Claudia Blümel

Elisabeth Nahrwold

Christoph Dahlhoff

Tara Arvedson

Irwin Chen

Julie Bailis

Jochen Pendzialek

Johannes Brozy

Joachim Wahl

The present invention provides bispecific antibody constructs characterized by comprising a first domain binding to MUC17, a second domain binding to an extracellular epitope of the human and theCD3ε chain and optionally a third domain, which is a specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.

Bispecific antibody construct directed to MUC17 and CD3

The present invention relates to an antibody construct comprising a domain which binds to Claudin 18.2 (CLDN18.2) and another domain which binds to CD3. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for producing the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.

Antibody constructs for CLDN18.2 and CD3

Growing community of inventors

Thousand Oaks, CA, United States of America

Sandra Ross